INCB050465

DRUG5 trials

Sponsors

Incyte Corporation

Conditions

Advanced MalignanciesBreast CancerColorectal Cancer (CRC)Endometrial CancerHead and Neck CancerLung CancerMMR-deficient TumorsMelanoma

Phase 1

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

TerminatedNCT02265510

Incyte CorporationAdvanced Malignancies, Metastatic Cancer, Solid Tumors

Start: 2014-09-10End: 2019-02-27Updated: 2020-04-17

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

TerminatedNCT02559492

Incyte CorporationSolid Tumors

Start: 2015-11-30End: 2019-08-18Updated: 2019-09-25

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

CompletedNCT02646748

Incyte CorporationBreast Cancer, Colorectal Cancer (CRC), Endometrial Cancer +8

Start: 2016-01-25End: 2020-11-20Updated: 2022-03-31

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

CompletedNCT03589651

Incyte CorporationUnresectable or Metastatic Solid Tumors

Start: 2018-08-17End: 2022-11-21Updated: 2023-02-21

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

CompletedNCT03688152

Incyte CorporationRefractory Diffuse Large B-Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma

Start: 2018-12-03End: 2020-09-01Updated: 2020-11-10

Related Papers

Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Cancer Research Communications2023-12-197 citations

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

Journal for ImmunoTherapy of Cancer2022-03-0114 citations

28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies

Regular and Young Investigator Award Abstracts2020-11-0117 citations

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus <i>nab</i>-Paclitaxel and Gemcitabine in Advanced Solid Tumors

The Oncologist2018-08-1643 citations